Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Poly (ADP-ribose) polymerase (PARP-)remmers bij het ovariumcarcinoom
sep 2018 | Gynaecologische oncologie